12:00 AM
Nov 11, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Theravance, GlaxoSmithKline sales and marketing update

GlaxoSmithKline and Theravance launched Breo Ellipta fluticasone furoate/vilanterol in the U.S. to treat airflow obstruction in patients with chronic obstructive pulmonary disease (COPD) and to reduce COPD exacerbations in patients with a history of exacerbations. The product's wholesale acquisition cost is $267.67 per month. Breo Ellipta is a once-daily, fixed-dose combination of the...

Read the full 252 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >